Six U.S. scientists have been awarded $1.25 million each over 5 years to conduct high-risk, high-reward cancer immunology research with the potential to transform cancer treatment
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by researchers at the University of California San Diego. In mouse models of colon cancer, the combination therapy eliminated all tumors and prevented their recurrence, which in turn resulted in 100% survival. The therapy also increased survival in mouse models of melanoma.
Researchers at UT Southwestern have developed a first-of-its-kind ultrasound-guided cancer immunotherapy platform that delivers immune-stimulating agents to cells for the development of systemic anti-tumor immunity. The technology, termed Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC), was described in a study published in Nature Nanotechnology.
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
In a new study, researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have brought insight into one crucial step in the anti-cancer immune response process: T cell priming.
Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.
In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.
Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
A new cancer immunotherapy pairs ultrasound with specially engineered CAR T cells to destroy malignant tumors while sparing normal tissue. The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.
Researchers at Washington University School of Medicine in St. Louis have shown in preclinical studies conducted in mice and human cells that a type immunotherapy based on natural killer cells could be effective against solid tumors, starting with melanoma, a type of skin cancer that can be deadly if not caught early.
The Weizmann Institute’s Prof. Yardena Samuels, Prof. Eran Segal, and Dr. Ravid Straussman, with partners at MD Anderson Cancer Center, the NCI, and elsewhere, have discovered that the bacteria living inside cancer cells can be harnessed to provoke an immune reaction against the tumor. The work could also help explain findings showing that the microbiome affects the success of immunotherapy.
A recently published paper addresses the threat posed by overstating the significance of inconclusive studies to the public by both the media and the scientific community itself.
The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.
Johns Hopkins Kimmel Cancer Center study co-author Bert Vogelstein, M.D., will present the related talk “Targeting genetic alterations in cancers with immunotherapeutic agents” at 11 a.m., March 1, at the Advances in Genome Biology and Technology (AGBT) conference. More information can be found at: https://www.agbt.org/events/general-meeting/agenda/. NOTE: AGBT provides complimentary press registration to staff and working freelance journalists who wish to cover the meeting. https://www.agbt.org/media/guidelines/
Researchers reporting in ACS’ Nano Letters have developed a hydrogel that, when injected into mice with melanoma, slowly released RNA nanovaccines that shrank tumors and kept them from metastasizing.
Scientists are hoping advances in cancer research could lead to a day when a patient’s own immune system could be used to fight and destroy a wide range of tumors. Cancer immunotherapy has some remarkable successes, but its effectiveness has been limited to a relatively small handful of cancers. In APL Bioengineering, researchers describe how advances in engineering models of tumors can greatly expand cancer immunotherapy’s effectiveness to a wider range of cancers.
Research Leader Christian Hinrichs, MD, has been named Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey,
During the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, leading scientific experts will dive into the groundbreaking advances that are the future of cancer care. One plenary session will focus on the cutting-edge treatment known as T cell therapy, while another will showcase recent discoveries about tumor metabolism that could lead to new, more effective cancer drugs.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.
Anita Kinney, professor at the Rutgers School of Public Health and associate director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is one of ten recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to support investigation into reducing racial health disparities in cancer care through precision oncology and immunotherapy.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.
Study in mice reveals new immune regulatory mechanism involved in cancer, viral infections
Silencing immune-regulating gene in immune cells eradicated colon cancer in mice
Approach also helped some animals clear an aggressive form of melanoma
Findings offer pathway for design of new class of immune-based cancer therapies
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at Children’s Hospital of Philadelphia, has been elected into the National Academy of Medicine (NAM), effective Oct. 1, 2019.
UC San Diego bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells. The system requires two “keys”—the drug Tamoxifen and blue light—to activate CAR T cells to bind to their targets. Just one key keeps the cells inactive.